Symbols

KPRX

Kiora Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KPRX

Kiora Pharmaceuticals, Inc.

A clinical-stage biotechnology company that develops the treatments for ophthalmic diseases

Industry

Pharmaceutical

Established Date

12/26/2004

Listing Date

07/31/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.kiorapharma.com

Security Type

Common stock

Office address

169 Saxony Rd., Suite 212, Encinitas, CA 92024

Business

Introduction

Kiora Pharmaceuticals, Inc., was incorporated as a Delaware corporation on December 26, 2004 under the name EyeGate Pharmaceuticals, Inc., and changed its name to Kiora Pharmaceuticals, Inc., effective November 8, 2021. The Company is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapies and drug delivery for the treatment of eye diseases.

Company Financials

EPS

KPRX has released its 2025 Q4 earnings. EPS was reported at -1.59, versus the expected -0.67, missing expectations. The chart below visualizes how KPRX has performed over recent quarters, highlighting trends in earnings surprises.